Recently, Hefei Hechen Biotechnology Co., Ltd. (hereinafter referred to as “Hechen Bio”) announced the completion of an A-round financing worth over RMB 100 million. Investors in this round include Anhui Venture Capital, Changxing Fund, Guoyuan Equity, Jiansu Capital, and industrial partner Shike New Materials.
According to public information, Hechen Bio was established in May 2022. Built on the technological foundation of “synthetic biology + precision chemistry,” the company is committed to becoming a globally leading bio-manufacturing enterprise integrating biosynthesized functional active ingredients and application solutions. At present, the company has established three major business segments: specialty material monomers, niche amino acids, and delivery formulation solutions. Its products are mainly applied in cosmetic ingredients, bio-based materials, specialty materials, and pharmaceutical intermediates.
In the cosmetics sector, Hechen Bio’s key ingredients include Ergothioneine, Ectoine, Pro-Xylane, Phloretin, and EUK-134. In recent years, responding to consumer demand for minimalist formulations and precise efficacy in skincare, the company has also independently developed its “Meixinqiu®” clean efficacy skincare products, achieving a full-chain closed-loop validation from in-house ingredient R&D and manufacturing to end-product commercialization.
Hechen Bio stated that the newly raised funds will be primarily invested in the construction of a thousand-ton-scale annual production base. The facility will adopt fully intelligent process control and modular flexible manufacturing design, serving as a key pillar for the company to break through development bottlenecks and seize market opportunities. In addition, the company plans to further introduce AI technologies to enhance and optimize its technology platform, accelerating the R&D and industrialization process of bio-manufacturing.
